This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Interferon α–induced retinopathy is well established in the literature. Fundus examination in these patients typically shows cotton wool spots and retinal hemorrhages in the macula and peripapillary region.1 The management of relapsing-remitting multiple sclerosis (MS) often involves interferon β therapy. Although interferon β shares many similar biochemical properties with interferon α, interferon β does not typically cause retinopathy. Only one report of interferon β retinopathy exists in the English literature and a definitive causal relationship remains unclear. We report a patient treated with interferon β-1a who developed retinopathy which resolved upon cessation of the drug.
Case report.
A 48-year-old woman with relapsing-remitting MS had blurry vision in the inferonasal quadrant of her right eye. Five months earlier the patient had begun interferon β-1a 44 μg SC three times per week. The patient had no other ocular complaints and no other past medical history.
On examination, the patient appeared well and her blood pressure was 114/76 mm Hg. Visual acuities were 20/20 at distance and near in each eye. Dilated fundus examination showed …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS
No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS
The application of optical coherence tomography in neurologic diseases
Optical coherence tomography and disease subtype in multiple sclerosis